Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
Ecancermedicalscience|August 3, 2023
Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in UgandaSiraji Obayo, Yusuf Mulumba, Cheryl L Thompson, et al.Investigational New Drugs|August 17, 2010
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinomaDale R Shepard, Matthew M Cooney, Paul Elson, et al.Current Opinion in Hematology|October 16, 2007
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosisWillem J van Heeckeren, Sharon L Sanborn, Ajita Narayan, et al.Journal of Vascular and Interventional Radiology : JVIR|March 25, 2014
Incidence of hypercoagulable events after image-guided percutaneous cryoablation of renal tumors: a single-center experienceJason B Hartman, Nicholas Bhojwani, David J Corn, et al.African Health Sciences|August 16, 2021
Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer InstituteClement D Okello, Yusuf Mulumba, Abrahams Omoding, et al.Cancer Chemotherapy and Pharmacology|August 10, 2012
Phase I trial of pomalidomide given for patients with advanced solid tumorsMatthew M Cooney, Charles Nock, Joseph Bokar, et al.Cancer Chemotherapy and Pharmacology|August 8, 2012
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumorsJoanna M Brell, Smitha S Krishnamurthi, Linda Rath, et al.Investigational New Drugs|May 13, 2008
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principlesSharon L Sanborn, Matthew M Cooney, Afshin Dowlati, et al.Urology|September 6, 2015
National Trends of Local Ablative Therapy Among Young Patients With Small Renal Masses in the United StatesJonathan E Kiechle, Robert Abouassaly, Marc C Smaldone, et al.Investigational New Drugs|November 18, 2008
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumorsSharon L Sanborn, Joseph Gibbons, Smitha Krishnamurthi, et al.Pageof 4